Bristol-Myers Squibb Co. (NYSE:BMY)’s share price was up 2.9% during mid-day trading on Tuesday . The company traded as high as $62.05 and last traded at $62.03, with a volume of 16,375,819 shares. The stock had previously closed at $60.30.

A number of equities analysts recently issued reports on BMY shares. Vetr downgraded shares of Bristol-Myers Squibb from a “sell” rating to a “strong sell” rating and set a $60.30 price target for the company. in a research note on Thursday, April 14th. Berenberg Bank reaffirmed a “buy” rating and set a $80.00 target price on shares of Bristol-Myers Squibb in a research note on Friday, April 22nd. Credit Suisse Group AG reaffirmed an “overweight” rating on shares of Bristol-Myers Squibb in a research note on Tuesday, April 26th. Leerink Swann reaffirmed a “buy” rating on shares of Bristol-Myers Squibb in a research note on Wednesday, April 27th. Finally, Barclays PLC raised their target price on shares of Bristol-Myers Squibb from $70.00 to $75.00 and gave the company an “equal weight” rating in a research note on Friday, April 29th. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and eleven have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $72.09.

The stock has a market cap of $102.94 billion and a PE ratio of 36.03. The company’s 50 day moving average is $73.40 and its 200 day moving average is $68.57.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, July 28th. The biopharmaceutical company reported $0.69 EPS for the quarter, topping the consensus estimate of $0.66 by $0.03. The firm had revenue of $4.90 billion for the quarter, compared to the consensus estimate of $4.60 billion. The company’s revenue was up 17.2% compared to the same quarter last year. During the same quarter last year, the firm earned $0.53 EPS. Analysts anticipate that Bristol-Myers Squibb Co. will post $2.63 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, November 1st. Shareholders of record on Friday, October 7th will be paid a dividend of $0.38 per share. The ex-dividend date is Wednesday, October 5th. This represents a $1.52 dividend on an annualized basis and a yield of 2.47%.

In other Bristol-Myers Squibb news, SVP Joseph C. Caldarella sold 3,519 shares of the company’s stock in a transaction that occurred on Monday, May 16th. The shares were sold at an average price of $72.47, for a total transaction of $255,021.93. Following the transaction, the senior vice president now owns 55,238 shares in the company, valued at approximately $4,003,097.86. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Lamberto Andreotti sold 23,200 shares of the company’s stock in a transaction that occurred on Friday, July 8th. The shares were sold at an average price of $74.45, for a total transaction of $1,727,240.00. Following the transaction, the director now owns 380,099 shares in the company, valued at approximately $28,298,370.55. The disclosure for this sale can be found here.

Other hedge funds and institutional investors recently modified their holdings of the company. Boltwood Capital Management raised its position in shares of Bristol-Myers Squibb by 1.3% in the fourth quarter. Boltwood Capital Management now owns 15,540 shares of the biopharmaceutical company’s stock worth $1,069,000 after buying an additional 200 shares during the last quarter. IronBridge Capital Management LP bought a new position in shares of Bristol-Myers Squibb during the fourth quarter worth about $1,079,000. Atlanta Capital Group raised its position in shares of Bristol-Myers Squibb by 3.4% in the fourth quarter. Atlanta Capital Group now owns 15,751 shares of the biopharmaceutical company’s stock worth $1,084,000 after buying an additional 522 shares during the last quarter. Homrich & Berg raised its position in shares of Bristol-Myers Squibb by 3.8% in the fourth quarter. Homrich & Berg now owns 18,171 shares of the biopharmaceutical company’s stock worth $1,250,000 after buying an additional 671 shares during the last quarter. Finally, Girard Partners LTD. raised its position in shares of Bristol-Myers Squibb by 15.6% in the fourth quarter. Girard Partners LTD. now owns 19,810 shares of the biopharmaceutical company’s stock worth $1,363,000 after buying an additional 2,672 shares during the last quarter.

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company operates in BioPharmaceuticals segment. Its pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes (involving recombinant deoxyribonucleic acid (DNA) technology) called biologics.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.